Why the study?
Does ambulatory blood pressure monitoring (ABPM) improve correlation with end-organ damage compared to clinic blood pressure in patients with hypertension?
Does ambulatory blood pressure monitoring (ABPM) improve correlation with end-organ damage compared to clinic blood pressure in patients with hypertension?
Answers are grounded in this paper and cite their sources.
Routine large-scale use of ABPM is not currently supported; its use should be restricted to specific indications like identifying white-coat hypertension in specialized centers until prospective prognostic data are available.
This report reviews the evidence for and against clinical use of ambulatory blood pressure monitoring (ABPM) on a large scale. Such monitoring is supported by a number of data, among which is that the end-organ damage associated with hypertension correlates more with 24-h average blood pressure than with clinic blood pressure, the correlation becoming even closer with addition of blood pressure variability values. However, the evidence thus far collected is largely cross-sectional. Furthermore, ABPM devices have limited accuracy and the procedure has a high cost. Therefore, while prospective studies on the prognostic value of ambulatory blood pressure are awaited, use of this approach should be restricted to a limited number of clinical circumstances (e.g., identification of white-coat hypertension) and used only in specialized centers.
No takes yet. Share an insight, caveat, or question.
Mancia et al. (1994) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: